Few clinical data are available to demonstrate the advantages of CTLA-4 ICIs combined with PD-1/PD-L1 ICIs over monotherapy in treating chordoma, and ICIs combination therapy shows more toxicity than monotherapy. Here, CD274 is linked to chordoma.